Study of Exenatide Once-Weekly Suspension in Chinese Patients with Type 2 Diabetes Mellitus

Trial Identifier:	D5553C00008
Sponsor:	AstraZeneca
NCTID::	NCT04001231
Start Date:	June 2020
Primary Completion Date:	July 2021
Study Completion Date:	July 2021
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Beijing, China, 100191
China	Shanghai, China, 200080
China	Shanghai, China, 200120
China	Suzhou, China, 215004

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.